Assembly Bioscie Financials
This page shows Assembly Bioscie (ASMB) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 19 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Financial Health Signals
Based on FY2025 annual data. Scores normalized against common benchmarks. How we calculate these scores
Assembly Bioscie has an operating margin of -16.8%, meaning the company retains $-17 of operating profit per $100 of revenue. This below-average margin results in a low score of 0/100, suggesting thin profitability after operating expenses. This is up from -159.3% the prior year.
Assembly Bioscie's revenue surged 153.5% year-over-year to $72.3M, reflecting rapid business expansion. This strong growth earns a score of 100/100.
Assembly Bioscie carries a low D/E ratio of 0.25, meaning only $0.25 of long-term debt for every $1 of shareholders' equity. This conservative leverage earns a score of 97/100, indicating a strong balance sheet with room for future borrowing.
With a current ratio of 5.22, Assembly Bioscie holds $5.22 in current assets for every $1 of short-term obligations. This comfortable liquidity earns a score of 100/100.
While Assembly Bioscie generated -$41.1M in operating cash flow, capex of $66K consumed most of it, leaving -$41.2M in free cash flow. This results in a low score of 0/100, reflecting heavy capital investment rather than weak cash generation.
Assembly Bioscie generates a -3.0% ROE, indicating limited profit relative to shareholders' investment. This results in a returns score of 5/100. This is up from -120.4% the prior year.
Assembly Bioscie passes 3 of 9 financial strength tests. 1 of 4 profitability signals pass, 1 of 3 leverage/liquidity signals pass, both operating efficiency signals pass.
For every $1 of reported earnings, Assembly Bioscie generates $6.71 in operating cash flow (-$41.1M OCF vs -$6.1M net income). This low ratio suggests earnings are primarily driven by accounting accruals rather than cash generation, which may not be sustainable.
Key Financial Metrics
Earnings & Revenue
Assembly Bioscie generated $72.3M in revenue in fiscal year 2025. This represents an increase of 153.5% from the prior year.
Assembly Bioscie's EBITDA was -$12.0M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 73.5% from the prior year.
Assembly Bioscie reported -$6.1M in net income in fiscal year 2025. This represents an increase of 84.8% from the prior year.
Assembly Bioscie earned $-0.55 per diluted share (EPS) in fiscal year 2025. This represents an increase of 91.8% from the prior year.
Cash & Balance Sheet
Assembly Bioscie generated -$41.2M in free cash flow in fiscal year 2025, representing cash available after capex. This represents an increase of 19.5% from the prior year.
Assembly Bioscie held $58.5M in cash against $0 in long-term debt as of fiscal year 2025.
Assembly Bioscie had 16M shares outstanding in fiscal year 2025. This represents an increase of 112.7% from the prior year.
Margins & Returns
Assembly Bioscie's operating margin was -16.8% in fiscal year 2025, reflecting core business profitability. This is up 142.5 percentage points from the prior year.
Assembly Bioscie's net profit margin was -8.5% in fiscal year 2025, showing the share of revenue converted to profit. This is up 132.4 percentage points from the prior year.
Assembly Bioscie's ROE was -3.0% in fiscal year 2025, measuring profit generated per dollar of shareholder equity. This is up 117.5 percentage points from the prior year.
Capital Allocation
Assembly Bioscie invested $64.8M in research and development in fiscal year 2025. This represents an increase of 15.9% from the prior year.
Assembly Bioscie invested $66K in capex in fiscal year 2025, funding long-term assets and infrastructure. This represents an increase of 135.7% from the prior year.
ASMB Income Statement
| Metric | Q2'26 | Q1'26 | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $10.8M+12.1% | $9.6M+2.2% | $9.4M+28.0% | $7.4M+7.5% | $6.8M-19.8% | $8.5M+47.5% | $5.8M | N/A |
| Cost of Revenue | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Gross Profit | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| R&D Expenses | $16.6M+2.9% | $16.1M+8.6% | $14.9M+4.0% | $14.3M+5.7% | $13.5M-16.9% | $16.3M+36.9% | $11.9M | N/A |
| SG&A Expenses | $5.1M+10.7% | $4.6M+1.9% | $4.5M-2.2% | $4.6M+7.5% | $4.3M-4.3% | $4.5M-3.4% | $4.6M | N/A |
| Operating Income | -$10.9M+1.9% | -$11.1M-11.6% | -$9.9M+13.8% | -$11.5M-5.3% | -$11.0M+10.2% | -$12.2M-13.7% | -$10.7M | N/A |
| Interest Expense | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Income Tax | $0 | $0 | N/A | N/A | $0-100.0% | $406K | N/A | N/A |
| Net Income | -$9.2M+9.8% | -$10.2M-15.6% | -$8.8M+14.7% | -$10.3M-7.5% | -$9.6M+13.8% | -$11.2M-22.9% | -$9.1M | N/A |
| EPS (Diluted) | $-0.72+45.9% | $-1.33-13.7% | $-1.17 | N/A | $-1.51+23.7% | $-1.98-19.3% | $-1.66 | N/A |
ASMB Balance Sheet
| Metric | Q2'26 | Q1'26 | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $240.0M+197.1% | $80.8M-18.4% | $99.0M-16.9% | $119.2M+18.9% | $100.3M-13.1% | $115.3M-3.8% | $119.9M-12.4% | $136.8M |
| Current Assets | $236.8M+205.7% | $77.5M-18.9% | $95.5M-17.3% | $115.5M+17.6% | $98.2M-13.0% | $112.9M-3.6% | $117.2M-12.4% | $133.8M |
| Cash & Equivalents | $22.5M-6.1% | $24.0M+2.5% | $23.4M-38.9% | $38.3M+34.8% | $28.5M+48.1% | $19.2M+2.4% | $18.7M-5.5% | $19.8M |
| Inventory | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Accounts Receivable | $912K | N/A | N/A | $0 | $0 | $0-100.0% | $43K0.0% | $43K |
| Goodwill | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Liabilities | $57.3M-8.6% | $62.7M-12.8% | $71.9M-16.2% | $85.8M+15.6% | $74.3M-7.9% | $80.6M-7.6% | $87.3M-8.8% | $95.7M |
| Current Liabilities | $53.4M+12.9% | $47.3M+1.4% | $46.6M-2.5% | $47.8M+14.8% | $41.6M+0.9% | $41.3M+6.5% | $38.8M-1.2% | $39.2M |
| Long-Term Debt | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Equity | $182.7M+909.4% | $18.1M-33.3% | $27.1M-18.7% | $33.4M+28.3% | $26.0M-25.0% | $34.7M+6.4% | $32.6M-20.7% | $41.1M |
| Retained Earnings | -$854.1M-1.1% | -$844.9M-1.2% | -$834.7M-1.1% | -$825.9M-1.3% | -$815.6M-1.2% | -$806.0M-1.4% | -$794.8M-1.2% | -$785.7M |
ASMB Cash Flow Statement
| Metric | Q2'26 | Q1'26 | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$15.1M+9.7% | -$16.8M+28.5% | -$23.4M-5659.0% | -$407K+97.3% | -$15.2M+10.9% | -$17.1M+6.9% | -$18.4M-124.9% | $73.6M |
| Capital Expenditures | $42K | $0 | $0 | $0 | $0-100.0% | $14K0.0% | $14K-80.3% | $71K |
| Free Cash Flow | -$15.2M+9.4% | -$16.8M+28.5% | -$23.4M-5659.0% | -$407K+97.3% | -$15.2M+10.9% | -$17.1M+6.9% | -$18.4M-125.0% | $73.6M |
| Investing Cash Flow | -$158.3M-1031.3% | $17.0M+158.0% | $6.6M+198.4% | -$6.7M-127.3% | $24.5M+379.5% | $5.1M-70.4% | $17.3M+119.3% | -$89.7M |
| Financing Cash Flow | $171.9M+48060.2% | $357K-81.4% | $1.9M-88.7% | $17.0M | $0-100.0% | $12.5M | $0-100.0% | $9.2M |
| Dividends Paid | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Share Buybacks | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
ASMB Financial Ratios
| Metric | Q2'26 | Q1'26 | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Operating Margin | -100.9%+14.4pp | -115.2%-9.7pp | -105.5%+51.2pp | -156.8%+3.3pp | -160.1%-17.1pp | -143.0%+42.5pp | -185.5% | N/A |
| Net Margin | -85.2%+20.7pp | -105.9%-12.3pp | -93.6%+46.9pp | -140.5%-0.0pp | -140.4%-9.8pp | -130.7%+26.2pp | -156.9% | N/A |
| Return on Equity | -5.0%+51.3pp | -56.3%-23.8pp | -32.5%-1.5pp | -31.0%+6.0pp | -37.0%-4.8pp | -32.2%-4.3pp | -27.8% | N/A |
| Return on Assets | -3.8%+8.8pp | -12.6%-3.7pp | -8.9%-0.2pp | -8.7%+0.9pp | -9.6%+0.1pp | -9.7%-2.1pp | -7.6% | N/A |
| Current Ratio | 4.44+2.8 | 1.64-0.4 | 2.05-0.4 | 2.42+0.1 | 2.36-0.4 | 2.74-0.3 | 3.02-0.4 | 3.41 |
| Debt-to-Equity | 0.31-3.1 | 3.46+0.8 | 2.65+0.1 | 2.57-0.3 | 2.86+0.5 | 2.33-0.4 | 2.68+0.3 | 2.33 |
| FCF Margin | -140.7%+33.4pp | -174.1%+74.8pp | -248.9%-243.3pp | -5.5%+217.2pp | -222.7%-22.1pp | -200.6%+117.1pp | -317.7% | N/A |
Similar Companies
Frequently Asked Questions
What is Assembly Bioscie's annual revenue?
Assembly Bioscie (ASMB) reported $72.3M in total revenue for fiscal year 2025. This represents a 153.5% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
How fast is Assembly Bioscie's revenue growing?
Assembly Bioscie (ASMB) revenue grew by 153.5% year-over-year, from $28.5M to $72.3M in fiscal year 2025.
Is Assembly Bioscie profitable?
No, Assembly Bioscie (ASMB) reported a net income of -$6.1M in fiscal year 2025, with a net profit margin of -8.5%.
What is Assembly Bioscie's EBITDA?
Assembly Bioscie (ASMB) had EBITDA of -$12.0M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.
What is Assembly Bioscie's operating margin?
Assembly Bioscie (ASMB) had an operating margin of -16.8% in fiscal year 2025, reflecting the profitability of core business operations before interest and taxes.
What is Assembly Bioscie's net profit margin?
Assembly Bioscie (ASMB) had a net profit margin of -8.5% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.
What is Assembly Bioscie's return on equity (ROE)?
Assembly Bioscie (ASMB) has a return on equity of -3.0% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.
What is Assembly Bioscie's free cash flow?
Assembly Bioscie (ASMB) generated -$41.2M in free cash flow during fiscal year 2025. This represents a 19.5% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is Assembly Bioscie's operating cash flow?
Assembly Bioscie (ASMB) generated -$41.1M in operating cash flow during fiscal year 2025, representing cash generated from core business activities.
What are Assembly Bioscie's total assets?
Assembly Bioscie (ASMB) had $257.6M in total assets as of fiscal year 2025, including both current and long-term assets.
What are Assembly Bioscie's capital expenditures?
Assembly Bioscie (ASMB) invested $66K in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.
How much does Assembly Bioscie spend on research and development?
Assembly Bioscie (ASMB) invested $64.8M in research and development during fiscal year 2025.
What is Assembly Bioscie's current ratio?
Assembly Bioscie (ASMB) had a current ratio of 5.22 as of fiscal year 2025, which is generally considered healthy.
What is Assembly Bioscie's debt-to-equity ratio?
Assembly Bioscie (ASMB) had a debt-to-equity ratio of 0.25 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is Assembly Bioscie's return on assets (ROA)?
Assembly Bioscie (ASMB) had a return on assets of -2.4% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
What is Assembly Bioscie's cash runway?
Based on fiscal year 2025 data, Assembly Bioscie (ASMB) had $58.5M in cash against an annual operating cash burn of $41.1M. This gives an estimated cash runway of approximately 17 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.
What is Assembly Bioscie's Piotroski F-Score?
Assembly Bioscie (ASMB) has a Piotroski F-Score of 3 out of 9, indicating weak financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7–9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Assembly Bioscie's earnings high quality?
Assembly Bioscie (ASMB) has an earnings quality ratio of 6.71x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
How financially healthy is Assembly Bioscie?
Assembly Bioscie (ASMB) scores 50 out of 100 on our Financial Profile, indicating moderate overall financial health. This composite score evaluates six dimensions: profitability (operating margin), revenue growth, leverage (debt-to-equity), liquidity (current ratio), cash flow quality (free cash flow margin), and shareholder returns (return on equity). Each dimension is normalized against standard financial benchmarks. Learn more in our complete guide to financial health indicators.